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Abstract The integrin family of cell adhesion receptors is
emerging as a promising target of anticancer therapy.
AlphaVbeta3 and alphaVbeta5 integrins are overexpressed
on both glioma cells and tumor vasculature. Cilengitide, the
most advanced specific integrin inhibitor in oncology, has
shown antitumor activity against glioma in early clinical
trials. Durable remissions have been observed in phase I
and phase II trials for recurrent glioblastoma (GBM) with
both lower and higher doses of cilengitide. Pilot trials in
newly diagnosed glioblastoma in conjunction with standard
chemoradiotherapy have been encouraging. Preclinical data
suggest synergy with concomitant chemo- and radiation
therapy. A pivotal phase III study (CENTRIC) in newly
diagnosed GBM patients is currently recruiting. This paper
summarizes the current understanding of the role of
integrins and their inhibition in gliomagenesis. The back-
ground and design of ongoing trials are outlined.
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Introduction
Integrins are heterodimeric transmembrane cell surface
receptors that play a key role in the crosstalk between the
cell and its surrounding stroma [1]. Twenty-four different
integrins have been identified to date. Integrins link the
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cytoskeleton to the extracellular matrix, and are recognized
to be key regulators of tissue structure. Integrins regulate
cell adhesion, migration, differentiation, proliferation, and
survival during physiological and pathological conditions,
including inflammation and cancer. Upon ligation to
extracellular ligands (i.e., matrix proteins such as collagens,
laminins, vitronectins and fibronectins), integrins activate
downstream signaling pathways in concert with growth
factor receptors, including platelet-derived growth factor
receptor (PDGFR), epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor receptor
(VEGFR).
Preclinical data indicate that integrins play a key role in
cancer initiation and progression [2]. They provide adhe-
sive, migratory, and survival cues to tumor cells and to cells
of the tumor microenvironment, including angiogenic
endothelial cells. The integrins alphaVbeta3 and alphaV-
beta5, among others, are highly expressed not only on the
tumor vasculature and angiogenic endothelial cells, but also
on tumor cells, including gliomas (reviewed in [3, 4]).
Consequently, integrins have been considered as a promis-
ing therapeutic target in cancer [5]. Monoclonal antibodies
and peptide-based integrin inhibitors are being investigated
for their potential therapeutic activity in various tumor
types. This strategy is in advanced stage clinical develop-
ment in glioblastoma, a highly vascular primary brain
tumor. The only integrin inhibitor being studied in glioma is
cilengitide, we therefore focus this short review on this
agent.
Preclinical data on integrins in glioma
In high-grade glioma, and in particular in glioblastoma,
overexpression of alphaVbeta3 integrin is well docu-
mented. Importantly, alphaVbeta3 integrin is expressed
both on angiogenic endothelial cells and on tumor cells
[6–8]. Molecular imaging of alphaVbeta3 expression using
the tracer [18F]Galacto-RGD and validation by immuno-
histochemistry revealed that alphaVbeta3 integrin expres-
sion was mainly confined to the tumor region and was
absent in normal tissue [9]. Selective alphaVbeta3 upregu-
lation in malignant gliomas suggests that integrin signaling
in glioblastoma has important functions. Emerging evi-
dence indicates that integrins promote glioblastoma adhe-
sion, migration and angiogenesis [10, 11]. In an autocrine
loop hypoxia will recruit alphaVbeta3 and alphaVbeta5
integrins and activate focal adhesion kinase (FAK). Integrin
inhibition decreases hypoxia-inducible factor 1alpha (HIF-
1alpha) and reduces thus tumor hypoxia, which may lead to
increased radiation sensitivity [12].
The integrin alpha6beta1 plays an important role for the
regulation of glioma-initiating cells in the perivascular
niche [13]. This integrin mediates the interaction of
glioma-initiating cells to laminin, an extracellular matrix
protein expressed in basement membranes, including those
supporting endothelial cells. This interaction provides an
anchorage for glioma-initiating cells within the perivascular
niche and supports their tumorigenic potential.
Given the role of integrins in promoting glioma growth,
invasion and angiogenesis, integrin inhibitors might be
ideal therapeutic tools with synergistic activities in con-
junction with already established therapeutic modalities,
i.e., radiation therapy and cytotoxic chemotherapy. Impor-
tantly, because of their antiangiogenic effects [14], integrin
inhibitors are expected to normalize the tumor vasculature,
which in turn might enhance the effects of radiation therapy
and chemotherapy. Indeed the efficacy of these two
therapeutic modalities depends on an effective blood
perfusion for oxygenation of the tumor (i.e., an important
condition for radiation-induced tumor cell killing) and
optimal drug delivery. Inhibition of alphaVbeta3 and
alphaVbeta5 integrins in hypoxic glioma cells by siRNA
decreases HIF-1alpha by regulating FAK. Silencing this
signaling cascade in established xenografts indeed reduced
hypoxia and decreased angiogenesis [12].
Interestingly, ionizing radiation induces ceramide-
mediated apoptosis of tumor endothelial cells, causing tumor
vessel disruption and delayed tumor growth [15]. Consistent
with a cytotoxic effect of radiotherapy on angiogenic vessels,
concomitant administration of antiangiogenic drugs
decreases endothelial cell survival. Anti-VEGF antibodies
(e.g., bevacizumab) [16], VEGFR inhibitors (e.g., AG-
013736) [17], mTOR inhibitors (e.g., RAD001) [18], and
integrin inhibition (cilengitide) [19] sensitize angiogenic
endothelial cells to ionizing radiation-induced death, thereby
enhancing tumor vascular damage induced by radiotherapy
and improving therapeutic response [20]. Irradiation of
glioma cells increases their expression of alphaVbeta3
integrin [21], thus integrin inhibition will further synergize
with radiation therapy.
Regarding clinical translation, targeting alphavbeta3 and
alphavbeta5 might reduce hypoxia and thus resistance to
radio- and/or chemotherapy [12]. Indeed, arresting integrin
signaling synergistically enhances the anti-glioma effect of
radiation therapy in vivo [22].
A recent preclinical study suggests that low concen-
trations of small molecular integrin inhibitors used as single
agents may stimulate angiogenesis and tumor growth in
experimental melanoma and Lewis Lung carcinoma mod-
els, through increased VEGF expression and VEGFR2
signaling [23]. The concentrations of the small molecular
integrin inhibitor cilengitide, measured in patients in
clinical trials, however, largely exceed the critical “proan-
giogenic” concentrations described in this preclinical study,
and therefore, paradoxical proangiogenic effects of small
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molecular integrin inhibitors in the clinical application
seem rather unlikely [24]. In fact, relative cerebral blood
volume and blood flow, measured by perfusion MRI,
remained stable or decreased among recurrent GBM
patients responding to cilengitide therapy in a prior phase
I study [25]. Durable and clinically relevant responses have
been observed with cilengitide monotherapy; ongoing
clinical studies administer cilengitide in combination with
radiotherapy and/or chemotherapy. Nevertheless, the dura-
ble therapeutic success will depend on the efficient
management of escape mechanisms occurring under anti-
integrin therapies [26, 27].
Integrin inhibition attenuates invasion and metastasis
secondary to radiation-induced angiogenesis inhibition
Vascular normalization may not be the only mechanism by
which integrin inhibitors synergize with radio-
chemotherapy. We have recently observed that high doses
of ionizing radiation locally suppress angiogenesis in vivo
and inhibited endothelial cell sprouting in vitro through a
cell-autonomous effect mediated by the TGFbeta receptor
ALK5 [28]. Tumors derived from oral squamous cell
carcinoma and from hepatoma cell lines growing within a
pre-irradiated bed had decreased microvascular density and
were smaller, but their margins were highly invasive. They
also had increased hypoxia and necrosis, and a more
aggressive behavior with a higher number of lung metas-
tases [29]. Thus, pre-irradiation of the tumor bed reduces
local tumor growth, likely due to acute metabolic starvation
secondary to suppressed angiogenesis, but at the same time
it may enhance local invasion and metastatic spreading,
possibly through increased hypoxia. We have identified the
cysteine-rich protein 61 (CYR61), a member of the CCN
(CYR61/CTGF/NOV) family of matricelluar proteins reg-
ulating cell growth, differentiation, survival and migration
in development, tissue remodeling and repair [30], and
integrin alphaVbeta5 (a receptor for CYR61) expressed by
tumor cells, as critical molecules that cooperate to promote
local invasion and distant metastases [29]. Importantly,
function-blocking anti-αV mAb 17E6 [29, 31] and
cilengitide-inhibited CYR61-mediated invasion and metas-
tasis formation of tumor cells growing in a pre-irradiated
bed. These results suggest that cilengitide may improve
cancer control in conjunction with radiotherapy by
attenuating some of the unwanted rebound effect of
radiation-induced inhibition of angiogenesis. Hypoxia is
well known to activate pro-invasive programs [32] and
select for resistant variants with invasive characteristics.
This view is consistent with a recent experimental study
demonstrating that selected inhibition of tumor angiogen-
esis by antiangiogenic drugs, including in experimental
glioma, results in increased invasion and metastasis
formation [33].
Cilengitide
Cilengitide (Merck KGaA, Darmstadt, Germany) is a
synthetic Arg-Gly-Asp (RGD) pentapeptide recognizing
the RGD ligand-binding motif (ligand binding site) on the
integrin receptors alphaVbeta3 and alphaVbeta5 [34, 35]
and competitively blocks integrin ligand binding. It was
shown to diminish angiogenesis in vitro [36]. In an
important early preclinical study, cilengitide markedly
suppressed tumor growth in a medulloblastoma and
orthotopic glioblastoma models (i.e., tumors were grown
in the brain), while no growth inhibition was demonstrated
in a heterotopic model (i.e., when tumors were grown in
the flank of nude mice), or when an inactive peptide was
used [37]. This suggests that the brain environment is
particularly susceptible to integrin inhibition and led to
subsequent clinical investigation.
In phase I studies cilengitide was administered twice
weekly by intravenous infusion over 1 h. No dose limiting
toxicity was observed with doses up to 2400 mg/m2. Peak
plasma concentrations that had shown antitumor effects in
preclinical models were achieved at doses ≥120 mg/m2 [25,
38–40]. The terminal half-life of cilengitide is 3–5 h,
suggesting the possibility of increased efficacy with a more
frequent administration or continuous infusion schedule.
Clinical experience with cilengitide in malignant glioma
Sustained responses in recurrent glioblastoma were seen
both with lower and higher doses of cilengitide as single
agent in two phase I trials in adult and pediatric patients
[25, 39]. Overall cilengitide was well tolerated, a maximal
tolerated dose not reached and a clinical benefit seen both
at higher and lower doses. Subsequent trials were initiated
with flat (not per m2) twice weekly dosing of cilengitide at
an intermediate lower (500 mg) and intermediate higher
(2000 mg) dose (Table 1). In a randomized phase II trial of
81 patients with recurrent glioblastoma, treatment was
administered at the lower and higher dose. Cilengitide
monotherapy was well tolerated independently of the dose.
Objective responses were achieved in 5% or 13% of
patients treated with 500 mg or 2000 mg, respectively.
Progression-free survival after 6 months was 10% and 15%,
whereas overall survival was in the range of 6.5 versus
9.9 months, respectively [41]. Recently, long-term survival
results were reported demonstrating a 4-year survival rate
of 2.4% (95%CI 0.2; 11%) in patients treated with the
lower dose, and 10.0% (95%CI 3.2; 21.5%) in patients
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treated with the higher dose of cilengitide [42]. Similarly, a
phase II randomized trial evaluating lower (500 mg) and
higher (2000 mg) doses cilengitide added to temozolomide
and radiotherapy (TMZ/RT) in newly diagnosed glioblas-
toma patients was reported in abstract form [43]. Median
survival was 18.9 months, with an estimated median
survival of 17 months and 21 months, for the lower and
higher dose, respectively. Finally, higher exposure of the
tumor tissue could be demonstrated in another randomized
trial evaluating 3 doses of either 500 mg or 2000 mg
cilengitide prior to tumor resection in recurrent disease.
Cilengitide concentrations were several-fold higher in the
tumor than the corresponding plasma concentrations,
demonstrating both excellent penetration through the
blood-tumor barrier and retention within the tumor. Impor-
tantly, safety could be confirmed and no increase in
bleeding complications or wound healing problems were
observed [44].
Consistently, the higher dose of cilengitide is favored
by exposure, responses, progression-free and overall
survival.
Based on a strong preclinical rationale of radiosensitiza-
tion and synergy with both cilengitide and irradiation and
TMZ, we designed in parallel to the above-mentioned trials
a phase II pilot trial of adding cilengitide (500 mg) to
standard chemoradiotherapy with TMZ (TMZ/RT→TMZ)
[45, 46].
In a multicenter pilot study on 52 patients, treatment
was well tolerated with no identifiable added toxicity.
The primary endpoint of progression-free survival at
6 months compared favorably with historical controls
(69% versus 54%) [46, 47]. Median survival was
16.1 months, with a 2-year survival rate of 35% [45].
Interestingly, the outcome was particularly good in
patients with a methylated O6-methylguanine–DNA meth-
yltransferase (MGMT) gene promoter, Such patients were
previously identified to particularly benefit from TMZ
chemotherapy [48]. This is consistent with the working
hypothesis, that antiangiogenic therapy may lead to
normalization of tumor vasculature, decrease of hypoxia,
improved drug delivery and enhanced cytotoxicity. In
addition, the currently used higher dose of 2000 mg
should also exert relevant direct antitumor activity and
directly synergize with standard chemoradiotherapy.
Building on our pilot experience and the consistent
encouraging results of the other clinical trials in malignant
glioma, Merck KGaA in collaboration with the European
Organisation for Research and Treatment of Cancer
(EORTC) and the Canadian Brain Tumor Consortium is
sponsoring a large prospective clinical phase III trial
(CENTRIC study, Fig. 1) [49]. Based on the suggested
synergy between normalized perfusion and active chemo-
therapy, only patients with a methylated MGMT are eligible.
This requires centralized upfront MGMT testing, and it is
the first prospective international clinical oncology trial
incorporating this novel molecular marker to homogenously
define the treated patient population. Other changes from
the previous phase II trial are the exclusive use of the
higher dose of cilengitide (2000 mg), and cilengitide
maintenance therapy for up to 18 months. In parallel a
separate 3-arm randomized phase II trial has been designed
for patients with MGMT unmethylated tumors (CORE
study). Here an intensified high-dose daily cilengitide
administration before radiotherapy is being explored. Early
data indicate that this schedule is well tolerated and safe,
and the trial is now ongoing in a multicenter setting. The
results of all completed brain tumor clinical trials using
cilengitide are summarized in Table 1.
Conclusions
The ongoing phase III CENTRIC trial is successfully
recruiting in a multi-national setting and is expected to be
completed by the end of the year 2010. Careful analysis of
data emerging from this trial will make an important
contribution to further defining the role on integrin inhibition
in malignant gliomas. The absence of significant toxicity and
excellent tolerance will allow to safely testing integrin-
inhibition in combination with other targeted and cytotoxic
agents. Combined inhibition of integrins and VEGF may lead
to further enhancement and increased antitumor effect, and
clinical evaluation of this concept is warranted.
Conflict of interest statement The authors have no significant
conflict of interest to declare. The paper was written by G. Tabatabai
and R. Stupp, with review, input, comments and final approval by all
authors. The authors have conducted and are conducting industry and/
or NCI-sponsored trials with cilengitide.
References
1. Takada Y, Ye X, Simon S (2007) The integrins. Genome Biol 8
(5):215. doi:10.1186/gb-2007-8-5-215
2. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer:
biological implications and therapeutic opportunities. Nat Rev
Cancer 10(1):9–22. doi:10.1038/nrc2748
3. Ruegg C, Mariotti A (2003) Vascular integrins: pleiotropic
adhesion and signaling molecules in vascular homeostasis and
angiogenesis. Cell Mol Life Sci 60(6):1135–1157
4. Avraamides CJ, Garmy-Susini B, Varner JA (2008) Integrins in
angiogenesis and lymphangiogenesis. Nat Rev Cancer 8(8):604–
617. doi:10.1038/nrc2353
5. Alghisi GC, Ruegg C (2006) Vascular integrins in tumor
angiogenesis: mediators and therapeutic targets. Endothelium 13
(2):113–135
6. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ,
Thon N, Goetz C, Kretzschmar HA, Tonn JC, Goldbrunner RH
Targ Oncol (2010) 5:175–181 179
(2008) Expression of integrin alphavbeta3 in gliomas correlates
with tumor grade and is not restricted to tumor vasculature. Brain
Pathol 18(3):378–386. doi:10.1111/j.1750-3639.2008.00137.x
7. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M,
Shimada H, Barsky L, Weinberg KI, Laug WE (2002) Alpha v-
integrin antagonist emd 121974 induces apoptosis in brain tumor
cells growing on vitronectin and tenascin. Int J Cancer 98(5):690–
697. doi:10.1002/ijc.10265
8. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC,
Strasser JF, Villani R, Cheresh DA, Black PM (2001) Alpha(v)
beta3 and alpha(v)beta5 integrin expression in glioma periphery.
Neurosurgery 49(2):380–389, discussion 390
9. Beer AJ, Haubner R, SarbiaM, GoebelM, Luderschmidt S, GrosuAL,
Schnell O, Niemeyer M, Kessler H,Wester HJ,WeberWA, Schwaiger
M (2006) Positron emission tomography using [18f]galacto-rgd
identifies the level of integrin alpha(v)beta3 expression in man. Clin
Cancer Res 12(13):3942–3949. doi:10.1158/1078-0432.CCR-06-0266
10. Wild-Bode C, Weller M, Wick W (2001) Molecular determinants
of glioma cell migration and invasion. J Neurosurg 94(6):978–
984. doi:10.3171/jns.2001.94.6.0978
11. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp
R, Weller M (2009) Cilengitide modulates attachment and
viability of human glioma cells, but not sensitivity to irradiation
or temozolomide in vitro. Neuro Oncol 11(6):747–756.
doi:10.1215/15228517-2009-012
12. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C,
Cohen-Jonathan Moyal E (2009) Alphavbeta3/alphavbeta5
integrins-fak-rhob: a novel pathway for hypoxia regulation in
glioblastoma. Cancer Res 69(8):3308–3316. doi:10.1158/0008-
5472.CAN-08-2158
13. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE,
Macswords J, Wu Q, Vasanji A, McLendon RE, Hjelmeland AB,
Rich JN (2010) Integrin alpha 6 regulates glioblastoma stem cells.
Cell Stem Cell 6(5):421–432. doi:10.1016/j.stem.2010.02.018
14. Ruegg C, Alghisi GC (2010) Vascular integrins: therapeutic and
imaging targets of tumor angiogenesis. Recent Results Cancer Res
180:83–101. doi:10.1007/978-3-540-78281-0_6
15. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S,
Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor
response to radiotherapy regulated by endothelial cell apoptosis.
Science 300(5622):1155–1159. doi:10.1126/science.1082504300/
5622/1155
16. Nieder C, Wiedenmann N, Andratschke NH, Astner ST, Molls M
(2007) Radiation therapy plus angiogenesis inhibition with
bevacizumab: rationale and initial experience. Rev Recent Clin
Trials 2(3):163–168
17. Fenton BM, Paoni SF (2007) The addition of ag-013736 to
fractionated radiation improves tumor response without function-
ally normalizing the tumor vasculature. Cancer Res 67(20):9921–
9928. doi:10.1158/0008-5472.CAN-07-1066
18. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE,
Lu B (2005) Enhanced radiation damage of tumor vasculature by
mtor inhibitors. Oncogene 24(35):5414–5422. doi:10.1038/sj.
onc.1208715
19. Albert JM, Cao C, Geng L, Leavitt L, Hallahan DE, Lu B (2006)
Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of
radiotherapy in endothelial cell and non-small-cell lung cancer
models. Int J Radiat Oncol Biol Phys 65(5):1536–1543.
doi:10.1016/j.ijrobp.2006.04.036
20. Wachsberger P, Burd R, Dicker AP (2004) Improving tumor
response to radiotherapy by targeting angiogenesis signaling
pathways. Hematol Oncol Clin North Am 18(5):1039–1057.
doi:10.1016/j.hoc.2004.06.007, viii
21. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W (2001)
Sublethal irradiation promotes migration and invasiveness of
glioma cells: implications for radiotherapy of human glioblasto-
ma. Cancer Res 61(6):2744–2750
22. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson
K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL
(2009) Radiation sensitization of glioblastoma by cilengitide has
unanticipated schedule-dependency. Int J Cancer 124(11):2719–
2727. doi:10.1002/ijc.24240
23. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson
SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT,
Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker
GC, Hodivala-Dilke KM (2009) Stimulation of tumor growth and
angiogenesis by low concentrations of RGD-mimetic integrin
inhibitors. Nat Med 15(4):392–400. doi:10.1038/nm.1941
24. Weller M, Reardon D, Nabors B, Stupp R (2009) Will integrin
inhibitors have proangiogenic effects in the clinic? Nat Med 15
(7):726. doi:10.1038/nm0709-726, author reply 727
25. Nabors B, Mikkelsen T, Rosenfeld S, Hochberg F, Shastry Akella
N, Fisher J, Cloud G, Zhang Y, Carson K, Wittemer S, Colvevas
D, Grossman S, for the NABTT CNS Consortium (2007) A phase
I and correlative biology study of cilengitide in patients with
recurrent malignant glioma. J Clin Oncol 25(13):1651–1657
26. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich
R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer
AG, Huber PE (2005) Inhibition of alpha(V)beta3 integrin
survival signaling enhances antiangiogenic and antitumor effects
of radiotherapy. Clin Cancer Res 11(17):6270–6279
27. Abdollahi A, Folkman J (2010) Evading tumor evasion: current
concepts and perspectives of anti-angiogenic cancer therapy. Drug
Resist Updat 13(1–2):16–28. doi:10.1016/j.drup.2009.12.001
28. Imaizumi N, Monnier Y, Hegi M, Mirimanoff RO, Ruegg C
(2010) Radiotherapy suppresses angiogenesis in mice through tgf-
betari/alk5-dependent inhibition of endothelial cell sprouting.
PLoS ONE 5(6):e11084. doi:10.1371/journal.pone.0011084
29. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi
GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R,
Mirimanoff RO, Goodman SL, Delorenzi M, Ruegg C (2008)
Cyr61 and alphaVbeta5 integrin cooperate to promote invasion
and metastasis of tumors growing in preirradiated stroma. Cancer
Res 68(18):7323–7331. doi:10.1158/0008-5472.CAN-08-0841
30. Leask A, Abraham DJ (2006) All in the ccn family: essential
matricellular signaling modulators emerge from the bunker. J Cell
Sci 119(Pt 23):4803–4810. doi:10.1242/jcs.03270
31. Mitjans F, Sander D, Adan J, Sutter A, Martinez JM, Jaggle CS,
Moyano JM, Kreysch HG, Piulats J, Goodman SL (1995) An anti-
alpha V-integrin antibody that blocks integrin function inhibits the
development of a human melanoma in nude mice. J Cell Sci 108
(Pt 8):2825–2838
32. Chan DA, Giaccia AJ (2007) Hypoxia, gene expression, and
metastasis. Cancer Metastasis Rev 26(2):333–339. doi:10.1007/
s10555-007-9063-1
33. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals
F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009)
Antiangiogenic therapy elicits malignant progression of tumors
to increased local invasion and distant metastasis. Cancer Cell 15
(3):220–231. doi:10.1016/j.ccr.2009.01.027
34. Xiong JP, Stehle T, Zhang R, Joachimiak A, Frech M, Goodman
SL, Arnaout MA (2002) Crystal structure of the extracellular
segment of integrin alphaVbeta3 in complex with an arg-gly-asp
ligand. Science 296(5565):151–155. doi:10.1126/science1069040
35. Goodman SL, Holzemann G, Sulyok GA, Kessler H (2002)
Nanomolar small molecule inhibitors for alphaV(beta)6, alphaV
(beta)5, and alphaV(beta)3 integrins. J Med Chem 45(5):1045–
1051. doi:jm0102598
36. Nisato RE, Tille JC, Jonczyk A, Goodman SL, Pepper MS (2003)
AlphaV beta 3 and alphav beta 5 integrin antagonists inhibit
180 Targ Oncol (2010) 5:175–181
angiogenesis in vitro. Angiogenesis 6(2):105–119. doi:10.1023/B:
AGEN.0000011801.98187.f25255607
37. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV,
Cheresh DA, Laug WE (2001) Preferential susceptibility of brain
tumors to the antiangiogenic effects of an alpha(V) integrin
antagonist. Neurosurgery 48(1):151–157
38. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C,
Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT
(2003) Phase I and pharmacokinetic study of continuous twice
weekly intravenous administration of cilengitide (EMD 121974),
a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in
patients with advanced solid tumours. Eur J Cancer 39(7):917–
926. doi:S0959804903000571
39. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen
RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM,
Kun LE (2008) Phase I clinical trial of cilengitide in children with
refractory brain tumors: pediatric brain tumor consortium study
pbtc-012. J Clin Oncol 26(6):919–924. doi:10.1200/
JCO.2007.14.1812
40. Stupp R, Ruegg C (2007) Integrin inhibitors reaching the clinic. J
Clin Oncol 25(13):1637–1638
41. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O’Neill A,
Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D,
Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM,
Nippgen J, Picard M, Nabors LB (2008) Randomized phase II
study of cilengitide, an integrin-targeting arginine-glycine-aspartic
acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol
26(34):5610–5617. doi:10.1200/JCO.2008.16.7510
42. Fink K, Mikkelsen T, Nabors LB, Ravin P, Plotkin SR, Schiff D,
Hicking C, Picard M, Reardon DA (2010) Long-term effects of
cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: a
randomized phase IIa study. Proc Am Soc Clin Oncol, J Clin
Oncol 28(suppl):15s, abstract 2010
43. Nabors L, Mikkelsen T, Batchelor T, Lesser G, Rosenfeld M, Ye
X, Piantadosi S, Olson J, Brem S, Grossman S (2009) Nabtt 0306:
A randomized phase II trial of EMD 121974 in conjunction with
concomitant and adjuvant temozolomide with radiation therapy in
patients with newly diagnosed glioblastoma multiforme (GBM).
Proc Am Soc Clin Oncol, J Clin Oncol 27:15s, suppl; abstract
2001
44. Gilbert M, Lamborn K, Lassman A, Cloughesy T, Chang S,
Lieberman F, Wen P, Poetzsch S, Picard M, Prados M, Kuhn J, for
the North American Brain Tumor Consortium (2007) Tumor
tissue delivery of cilengitide fater intravenous administration to
patients with recurrent glioblastoma. Preliminary data from
NABTC protocol 03–02. Neuro Oncol 4:525
45. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U,
Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M,
Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica
A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/
IIa study of cilengitide and temozolomide with concomitant
radiotherapy followed by cilengitide and temozolomide mainte-
nance therapy in patients with newly diagnosed glioblastoma. J
Clin Oncol 28(16):2712–2718. doi:10.1200/JCO.2009.26.6650
46. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,
Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U,
Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A,
Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 352(10):987–996
47. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ,
Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P,
Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K,
Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe
D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy
with concomitant and adjuvant temozolomide versus radiotherapy
alone on survival in glioblastoma in a randomised phase III study:
5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10
(5):459–466. doi:10.1016/S1470-2045(09)70025-7
48. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N,
Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L,
Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC,
Stupp R (2005) MGMT gene silencing and benefit from
temozolomide in glioblastoma. N Engl J Med 352(10):997–1003
49. Stupp R, Van Den Bent MJ, Erridge SC, Reardon DA, Hong Y,
Wheeler H, Hegi M, Perry JR, Picard M, Weller M (2010)
Cilengitide in newly diagnosed glioblastoma with MGMT pro-
moter methylation: protocol of a multicenter, randomized, open-
label, controlled phase III trial (CENTRIC). Proc Am Soc Clin
Oncol, J Clin Oncol 28:15s, suppl; abstr TPS152
Targ Oncol (2010) 5:175–181 181
